Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.

What was studied

This trial tested epcoritamab with rituximab and lenalidomide. The patients had not had care for follicular lymphoma. Epcoritamab is a bispecific antibody that is given under the skin. The trial was open-label and mid-stage. It ran at 20 hospitals in Europe and in the USA. It set out to report 3-year activity and safety. 41 patients were in the analysis.

What they found

At about 3 years, 39 of 41 patients had a response. The most common severe events were neutropenia and infections. Neutropenia hit 20 patients. Infections hit 12. 29 patients had serious events. Cytokine release syndrome hit 13. Serious infections hit 13. 3 patients died of causes linked to the treatment. These were septic shock, PML and COVID-19.

What it means for patients

The authors say the mix showed high activity as first care. Response held over 3 years of follow-up. They say it warrants more analysis. The aim is to define its role.

Why it is not certain yet

The group was small, with 41 patients. The study is ongoing. Serious events were common. 3 patients died of treatment-related causes. The authors say more analysis is needed.

Source

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.